Therapy Areas: Central Nervous System
Cyclerion Therapeutics Beacon Biosignals extend and expand collaboration
9 July 2021 -

United States-based Cyclerion Therapeutics Inc (Nasdaq: CYCN) and United States-based Beacon Biosignals announced on Thursday that they have extended and expanded their strategic collaboration.

This partnership is intended to identify disease-relevant biomarkers to refine patient selection and endpoints to guide the clinical development of Cyclerion's investigational therapeutics for neurological diseases associated with cognitive impairment.

Both firms previously collaborated on the analysis of data from a Cyclerion clinical translational pharmacology study of CY6463, which showcased clear effects on EEG parameters associated with aging and disease. The product is an oral, first-in-class, central nervous system penetrant sGC stimulator that is being produced for neurological diseases associated with cognitive impairment.

Login
Username:

Password:


Related Headlines